|
JP5191537B2
(ja)
|
2007-06-18 |
2013-05-08 |
エム・エス・ディー・オス・ベー・フェー |
ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
WO2017030823A2
(en)
*
|
2015-08-14 |
2017-02-23 |
Merck Sharp & Dohme Corp. |
Anti-tigit antibodies
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
TWI640536B
(zh)
|
2016-06-20 |
2018-11-11 |
克馬伯有限公司 |
抗體
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
EP3497128A2
(en)
|
2016-08-09 |
2019-06-19 |
Kymab Limited |
Anti-icos antibodies
|
|
TW202436356A
(zh)
|
2016-10-11 |
2024-09-16 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
CA3044664C
(en)
|
2016-11-30 |
2022-11-22 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
|
MX2019010206A
(es)
*
|
2017-02-28 |
2019-12-11 |
Seattle Genetics Inc |
Anticuerpos anti inmunorreceptor de linfocitos t con dominios de motivo de inactivación basado en tirosina de inmunorreceptor e inmunoglobulina (tigit).
|
|
US11021537B2
(en)
*
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
|
AU2018263868A1
(en)
|
2017-05-02 |
2019-12-12 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
WO2018220446A1
(en)
|
2017-06-01 |
2018-12-06 |
Compugen Ltd. |
Triple combination antibody therapies
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
GB201709808D0
(en)
*
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
IL272227B2
(en)
*
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
WO2019062832A1
(zh)
|
2017-09-29 |
2019-04-04 |
江苏恒瑞医药股份有限公司 |
Tigit抗体、其抗原结合片段及医药用途
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
TWI877769B
(zh)
*
|
2017-12-30 |
2025-03-21 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
KR102511268B1
(ko)
*
|
2018-02-06 |
2023-03-20 |
아이-맵 바이오파마 (항저우) 컴퍼니 리미티드 |
Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
|
|
KR102825164B1
(ko)
|
2018-03-27 |
2025-06-26 |
브리스톨-마이어스 스큅 컴퍼니 |
자외선 신호를 사용한 단백질 농도의 실시간 모니터링
|
|
AU2019310803B2
(en)
*
|
2018-07-25 |
2022-11-03 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-TIGIT antibody and uses thereof
|
|
TW202023625A
(zh)
|
2018-08-23 |
2020-07-01 |
美商西雅圖遺傳學公司 |
抗tigit抗體
|
|
CN109384846B
(zh)
*
|
2018-09-25 |
2020-03-03 |
合肥瑞达免疫药物研究所有限公司 |
能够结合tigit的抗体或其抗原结合片段及用途
|
|
JP7467438B2
(ja)
|
2018-10-18 |
2024-04-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｒｓｖ抗体の製剤及びその使用方法
|
|
CN113015748B
(zh)
|
2018-10-31 |
2025-12-12 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
EP3898677A1
(en)
|
2018-12-21 |
2021-10-27 |
OSE Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
|
US12312401B2
(en)
|
2019-01-07 |
2025-05-27 |
Iteos Belguim Sa |
Anti-TIGIT antibodies
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
CN109734806B
(zh)
*
|
2019-03-15 |
2022-07-01 |
安徽安科生物工程（集团）股份有限公司 |
一种全人源抗huTIGIT单克隆抗体及其应用
|
|
US20220220430A1
(en)
|
2019-05-23 |
2022-07-14 |
Bristol-Myers Squibb Company |
Methods of monitoring cell culture media
|
|
CN114269782B
(zh)
*
|
2019-07-15 |
2023-12-29 |
上海君实生物医药科技股份有限公司 |
抗tigit抗体及其应用
|
|
JP7628111B2
(ja)
*
|
2019-09-03 |
2025-02-07 |
バイオ － テラ ソリューションズ、リミテッド |
抗ｔｉｇｉｔ免疫阻害剤及び応用
|
|
IL292757A
(en)
*
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Anti-tigit antibodies and uses thereof
|
|
JP7657794B2
(ja)
*
|
2019-11-15 |
2025-04-07 |
サーフェス、アンコロジー、インコーポレイテッド |
免疫療法のための組成物及び方法
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
US11396647B2
(en)
|
2020-01-07 |
2022-07-26 |
Board Of Regents, The University Of Texas System |
Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
EP4094777A4
(en)
*
|
2020-01-21 |
2024-01-24 |
Innovent Biologics (Suzhou) Co., Ltd. |
RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
|
|
CN115362270A
(zh)
|
2020-01-29 |
2022-11-18 |
得克萨斯州大学系统董事会 |
Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途
|
|
EP4096789A4
(en)
|
2020-01-29 |
2023-10-11 |
Board of Regents, The University of Texas System |
USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS
|
|
CN115244084A
(zh)
*
|
2020-03-06 |
2022-10-25 |
瑞泽恩制药公司 |
抗gitr抗体及其用途
|
|
JP7705873B2
(ja)
|
2020-03-13 |
2025-07-10 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Ｐｖｒｉｇ結合タンパク質及びその医薬用途
|
|
EP4147053B1
(en)
|
2020-05-07 |
2026-01-28 |
Institut Curie |
Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
|
|
CN114507284B
(zh)
*
|
2020-05-09 |
2023-05-26 |
华博生物医药技术（上海）有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
WO2021258337A1
(en)
*
|
2020-06-24 |
2021-12-30 |
Huahui Health Ltd. |
Human monoclonal antibodies against tigit for immune related diseases
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
WO2022105872A1
(zh)
*
|
2020-11-23 |
2022-05-27 |
广东菲鹏制药股份有限公司 |
抗tigit抗体或其抗原结合片段
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
WO2022124864A1
(ko)
*
|
2020-12-10 |
2022-06-16 |
주식회사 유틸렉스 |
항-tigit 항체 및 이의 용도
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
CA3213917A1
(en)
|
2021-04-09 |
2022-10-13 |
Nicolas Poirier |
New scaffold for bifunctional molecules with improved properties
|
|
WO2022214652A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
TW202304965A
(zh)
|
2021-05-04 |
2023-02-01 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
|
|
BR112023023453A8
(pt)
|
2021-05-10 |
2024-02-15 |
Medimabbio Inc |
Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste, composições farmacêuticas e usos do referido anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste
|
|
WO2023010100A1
(en)
*
|
2021-07-28 |
2023-02-02 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel anti-sirpa antibodies
|
|
JP2024527049A
(ja)
|
2021-07-28 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
CA3231320A1
(en)
|
2021-09-15 |
2023-03-23 |
Zhiliang CAO |
Protein specifically binding to pd-1 and pharmaceutical use thereof
|
|
CN117858903A
(zh)
|
2021-09-15 |
2024-04-09 |
江苏恒瑞医药股份有限公司 |
一种含抗pvrig/tigit双特异性抗体的药物组合物
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
WO2023138639A1
(zh)
*
|
2022-01-24 |
2023-07-27 |
原启生物科技(上海)有限责任公司 |
靶向tigit的抗原结合蛋白及其用途
|
|
JP2025509274A
(ja)
|
2022-03-09 |
2025-04-11 |
ブリストル－マイヤーズ スクイブ カンパニー |
治療用タンパク質の一過性発現
|
|
PE20251671A1
(es)
|
2022-03-15 |
2025-06-30 |
Compugen Ltd |
Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
|
|
KR20250006250A
(ko)
*
|
2022-04-29 |
2025-01-10 |
머크 샤프 앤드 돔 엘엘씨 |
항-pd-1 항체와 조합된 항-ilt4 항체 또는 그의 항원-결합 단편의 안정한 제제 및 그의 사용 방법
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
JP2025525886A
(ja)
|
2022-08-02 |
2025-08-07 |
オーエスイー・イミュノセラピューティクス |
Ｃｄ２８に対する多機能性分子
|
|
EP4577574A1
(en)
*
|
2022-08-26 |
2025-07-02 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies targeting tigit and uses thereof
|
|
EP4681729A1
(en)
|
2023-03-15 |
2026-01-21 |
Shanghai Mabgen Biotech Ltd. |
Pharmaceutical composition containing pd-1/pvrig/tigit binding protein and medical use thereof
|
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
EP4687990A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|